CL2016001055A1 - Compuestos derivados de fenil-aminopirimidina, inhibidores de la tirosina quinasa de bruton (btk), composicion farmaceutica; combinacion farmaceutica; útiles en el tratamiento de enfermedades autoinmunes, inflamatorias, alergicas, de las vias aereas, entre otras. - Google Patents
Compuestos derivados de fenil-aminopirimidina, inhibidores de la tirosina quinasa de bruton (btk), composicion farmaceutica; combinacion farmaceutica; útiles en el tratamiento de enfermedades autoinmunes, inflamatorias, alergicas, de las vias aereas, entre otras.Info
- Publication number
- CL2016001055A1 CL2016001055A1 CL2016001055A CL2016001055A CL2016001055A1 CL 2016001055 A1 CL2016001055 A1 CL 2016001055A1 CL 2016001055 A CL2016001055 A CL 2016001055A CL 2016001055 A CL2016001055 A CL 2016001055A CL 2016001055 A1 CL2016001055 A1 CL 2016001055A1
- Authority
- CL
- Chile
- Prior art keywords
- btk
- treatment
- autoimmune
- inflammatory
- airways
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
COMPUESTOS DERIVADOS DE AMINOPIRIMIDINA, INHIBIDORES SELECTIVOS DE BTK; COMPOSICION FARMACEUTICA; COMBINACION FARMACEUTICA; USO EN EL TRATAMIENTO DE TRASTORNOS AUTOINMUNES, ENFERMEDADES INFLAMATORIAS TALES COMO ASMA Y EPOC, RECHAZO DE TRASPLANTES Y CANCER.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13195081 | 2013-11-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2016001055A1 true CL2016001055A1 (es) | 2016-10-28 |
Family
ID=49674216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2016001055A CL2016001055A1 (es) | 2013-11-29 | 2016-05-03 | Compuestos derivados de fenil-aminopirimidina, inhibidores de la tirosina quinasa de bruton (btk), composicion farmaceutica; combinacion farmaceutica; útiles en el tratamiento de enfermedades autoinmunes, inflamatorias, alergicas, de las vias aereas, entre otras. |
Country Status (43)
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗-cd19嵌合抗原受體治療癌症 |
US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
PL3129470T3 (pl) | 2014-04-07 | 2021-11-29 | Novartis Ag | Leczenie nowotworu złośliwego z zastosowaniem chimerycznego receptora antygenowego anty-CD19 |
JP2017528433A (ja) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のmTOR阻害剤とCARの組み合わせ |
WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
BR112017001183A2 (pt) | 2014-07-21 | 2017-11-28 | Novartis Ag | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado |
KR102594343B1 (ko) | 2014-07-21 | 2023-10-26 | 노파르티스 아게 | Cd33 키메라 항원 수용체를 사용한 암의 치료 |
ES2781175T3 (es) | 2014-07-31 | 2020-08-31 | Novartis Ag | Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico |
CA2958200A1 (en) | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using a gfr alpha-4 chimeric antigen receptor |
CN107108744B (zh) | 2014-08-19 | 2020-09-25 | 诺华股份有限公司 | 抗cd123嵌合抗原受体(car)用于癌症治疗 |
BR112017005390A2 (pt) | 2014-09-17 | 2017-12-12 | Novartis Ag | células citotóxicas alvo com receptores quiméricos para imunoterapia adotiva |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
JP6815992B2 (ja) | 2014-10-08 | 2021-01-20 | ノバルティス アーゲー | キメラ抗原受容体療法に対する治療応答性を予測するバイオマーカーおよびその使用 |
EP4245376A3 (en) | 2014-10-14 | 2023-12-13 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
WO2016090034A2 (en) | 2014-12-03 | 2016-06-09 | Novartis Ag | Methods for b cell preconditioning in car therapy |
US20180140602A1 (en) * | 2015-04-07 | 2018-05-24 | Novartis Ag | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
WO2016164731A2 (en) | 2015-04-08 | 2016-10-13 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell |
WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
DK3317301T3 (da) | 2015-07-29 | 2021-06-28 | Immutep Sas | Kombinationsterapier omfattende antistofmolekyler mod lag-3 |
MX2018007423A (es) | 2015-12-17 | 2018-11-09 | Novartis Ag | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas. |
WO2017112741A1 (en) | 2015-12-22 | 2017-06-29 | Novartis Ag | Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy |
CN109153714A (zh) | 2016-03-04 | 2019-01-04 | 诺华股份有限公司 | 表达多重嵌合抗原受体(car)分子的细胞及其用途 |
CN109641947B (zh) | 2016-07-20 | 2023-04-14 | 犹他大学研究基金会 | Cd229 car t细胞及其使用方法 |
BR112019006781A2 (pt) | 2016-10-07 | 2019-07-30 | Novartis Ag | receptores de antígeno quiméricos para o tratamento de câncer |
AU2017368333A1 (en) | 2016-12-03 | 2019-06-13 | Juno Therapeutics, Inc. | Methods for determining CAR-T cells dosing |
WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
US20200179511A1 (en) | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
CA3065120A1 (en) | 2017-06-02 | 2018-12-06 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
CN111050545A (zh) | 2017-06-29 | 2020-04-21 | 朱诺治疗学股份有限公司 | 评估与免疫疗法相关的毒性的小鼠模型 |
SG11202003501XA (en) | 2017-11-01 | 2020-05-28 | Juno Therapeutics Inc | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen |
US20210132042A1 (en) | 2017-11-01 | 2021-05-06 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
AU2018360800A1 (en) | 2017-11-01 | 2020-05-14 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for B-cell maturation antigen (BCMA) |
TWI694995B (zh) | 2017-11-06 | 2020-06-01 | 美商美國禮來大藥廠 | Btk抑制劑化合物 |
KR20200116081A (ko) | 2017-12-01 | 2020-10-08 | 주노 쎄러퓨티크스 인코퍼레이티드 | 유전자 조작된 세포의 투약 및 조절 방법 |
CN108069911A (zh) * | 2017-12-14 | 2018-05-25 | 中国药科大学 | 6-氨基-2-苯基嘧啶类化合物、制备方法和医药用途 |
MA51184A (fr) | 2017-12-15 | 2020-10-21 | Juno Therapeutics Inc | Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés |
EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
EP3801769A1 (en) | 2018-05-25 | 2021-04-14 | Novartis AG | Combination therapy with chimeric antigen receptor (car) therapies |
BR112020025048A2 (pt) | 2018-06-13 | 2021-04-06 | Novartis Ag | Receptores de antígeno quimérico de bcma e usos dos mesmos |
PE20210406A1 (es) | 2018-07-25 | 2021-03-02 | Novartis Ag | Inhibidores de inflamasoma nlrp3 |
PE20211058A1 (es) | 2018-11-01 | 2021-06-07 | Juno Therapeutics Inc | Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d) |
CN113646335A (zh) | 2018-11-01 | 2021-11-12 | 朱诺治疗学股份有限公司 | 使用对b细胞成熟抗原具有特异性的嵌合抗原受体的治疗的方法 |
MX2021005734A (es) | 2018-11-16 | 2021-09-10 | Juno Therapeutics Inc | Metodos de dosificacion de celulas t modificadas para el tratamiento de malignidades de celulas b. |
JP2022513685A (ja) | 2018-11-30 | 2022-02-09 | ジュノー セラピューティクス インコーポレイテッド | 養子細胞療法を用いた処置のための方法 |
US20220096651A1 (en) | 2019-01-29 | 2022-03-31 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1) |
AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
WO2020234780A1 (en) | 2019-05-23 | 2020-11-26 | Novartis Ag | Methods of treating asthma using a bruton's tyrosine kinase inhibitor |
CN113811301A (zh) * | 2019-05-23 | 2021-12-17 | 诺华股份有限公司 | 使用布鲁顿酪氨酸激酶抑制剂治疗舍格伦综合征的方法 |
MX2021014157A (es) | 2019-05-23 | 2022-01-04 | Novartis Ag | Formas cristalinas de un inhibidor btk. |
CN113795255A (zh) * | 2019-05-23 | 2021-12-14 | 诺华股份有限公司 | 使用布鲁顿酪氨酸激酶抑制剂治疗慢性自发性荨麻疹的方法 |
EP4081514A1 (en) * | 2019-12-23 | 2022-11-02 | Biogen MA Inc. | Btk inhibitors |
WO2021207689A2 (en) | 2020-04-10 | 2021-10-14 | Juno Therapeutics, Inc. | Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen |
CN116209444A (zh) * | 2020-08-14 | 2023-06-02 | 苏州晶云药物科技股份有限公司 | 苯甲酰胺类化合物的晶型及其制备方法 |
BR112023002031A2 (pt) | 2020-08-14 | 2023-03-07 | Novartis Ag | Derivados de espiropiperidinila substituídos por heteroarila e usos farmacêuticos dos mesmos |
WO2022162513A1 (en) | 2021-01-26 | 2022-08-04 | Novartis Ag | Pharmaceutical composition |
EP4313023A1 (en) | 2021-04-02 | 2024-02-07 | Biogen MA Inc. | Combination treatment methods of multiple sclerosis |
CA3229887A1 (en) | 2021-09-03 | 2023-03-09 | Novartis Ag | Lou064 for treating multiple sclerosis |
TW202322820A (zh) | 2021-12-14 | 2023-06-16 | 瑞士商諾華公司 | 使用lou064之治療方法 |
TW202342048A (zh) | 2022-02-28 | 2023-11-01 | 瑞士商諾華公司 | 使用lou064治療化膿性汗腺炎之方法 |
WO2023250400A1 (en) | 2022-06-22 | 2023-12-28 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
US20240067627A1 (en) | 2022-08-03 | 2024-02-29 | Novartis Ag | Nlrp3 inflammasome inhibitors |
US20240041929A1 (en) | 2022-08-05 | 2024-02-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for gprc5d and bcma |
WO2024069507A1 (en) | 2022-09-30 | 2024-04-04 | Novartis Ag | Synthesis methods and intermediates for the production of remibrutinib |
CN117024354B (zh) * | 2023-10-08 | 2023-12-08 | 天津凯莱英制药有限公司 | 瑞米布替尼的制备方法 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6303652B1 (en) | 1998-08-21 | 2001-10-16 | Hughes Institute | BTK inhibitors and methods for their identification and use |
GB0005345D0 (en) | 2000-03-06 | 2000-04-26 | Mathilda & Terence Kennedy Ins | Methods of treating sepsis septic shock and inflammation |
WO2002038797A2 (en) | 2000-10-23 | 2002-05-16 | Bristol-Myers Squibb Company | Modulators of bruton's tyrosine kinase, their identification and use |
KR20080014934A (ko) | 2000-11-07 | 2008-02-14 | 노파르티스 아게 | 단백질 키나제 c 억제제로서의 인돌릴말레이미드 유도체 |
AR036053A1 (es) | 2001-06-15 | 2004-08-04 | Versicor Inc | Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas |
PE20040079A1 (es) | 2002-04-03 | 2004-04-19 | Novartis Ag | Derivados de indolilmaleimida |
EP2322200A3 (en) | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
JP2006514021A (ja) | 2002-12-09 | 2006-04-27 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム | Janusチロシンキナーゼ3(Jak3)を選択的に阻害するための方法 |
JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
EP1473039A1 (en) | 2003-05-02 | 2004-11-03 | Centre National De La Recherche Scientifique (Cnrs) | Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis |
US7417065B2 (en) | 2003-05-19 | 2008-08-26 | Irm Llc | Immunosuppressant compounds and compositions |
EP1704145B1 (en) | 2004-01-12 | 2012-06-13 | YM BioSciences Australia Pty Ltd | Selective kinase inhibitors |
ES2543607T3 (es) | 2005-03-10 | 2015-08-20 | Gilead Connecticut, Inc. | Ciertas amidas sustituidas, método de obtención, y método de su uso |
JP2010502751A (ja) | 2006-09-11 | 2010-01-28 | シージーアイ ファーマシューティカルズ,インコーポレイティド | キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法 |
AR063946A1 (es) * | 2006-09-11 | 2009-03-04 | Cgi Pharmaceuticals Inc | Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
SI2526771T1 (sl) | 2006-09-22 | 2017-06-30 | Pharmacyclics Llc | Inhibitorji Bruton tirozin kinaze |
JP5832721B2 (ja) | 2007-03-14 | 2015-12-16 | バイオンシル・エス.アール.エル.Bionsil S.R.L. | 上皮腫瘍細胞における薬剤耐性のモジュレータ化合物 |
AU2009244291B2 (en) | 2008-05-06 | 2014-02-13 | Genentech, Inc. | Substituted amides, method of making, and use as Btk inhibitors |
MX2010013478A (es) | 2008-07-02 | 2010-12-20 | Hoffmann La Roche | Nuevas fenilpirazinonas como inhibidores de cinasa. |
CA2730930C (en) | 2008-07-16 | 2015-01-13 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
US20100261776A1 (en) | 2008-11-07 | 2010-10-14 | The Research Foundation Of State University Of New York | Bruton's tyrosine kinase as anti-cancer drug target |
US8299077B2 (en) * | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
SG175287A1 (en) | 2009-04-24 | 2011-11-28 | Hoffmann La Roche | Inhibitors of bruton's tyrosine kinase |
AR080328A1 (es) * | 2010-02-26 | 2012-03-28 | Boehringer Ingelheim Int | Tienopirimidinas que contienen un grupo alquilo sustituido inhibidoras de quinasas mnk1 y/o mnk2, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de trastornos metabolicos tales como diabetes y obesidad, y trastornos hiperproliferativos, entre otros |
UY33241A (es) * | 2010-02-26 | 2011-09-30 | Boehringer Ingelheim Int | ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?. |
US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
JP6147727B2 (ja) | 2011-04-01 | 2017-06-14 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | チロシン受容体キナーゼbtk阻害剤としての置換n−(3−(ピリミジン−4−イル)フェニル)アクリルアミド類似体 |
WO2012158843A2 (en) | 2011-05-17 | 2012-11-22 | The Regents Of The University Of California | Kinase inhibitors |
AU2012267491B2 (en) | 2011-06-10 | 2017-07-06 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity |
AU2012275275A1 (en) | 2011-06-28 | 2014-01-23 | Pharmacyclics Llc | Methods and compositions for inhibition of bone resorption |
EP2729466B1 (en) | 2011-07-08 | 2015-08-19 | Novartis AG | Novel pyrrolo pyrimidine derivatives |
US9273317B2 (en) | 2011-08-09 | 2016-03-01 | Fred Hutchinson Cancer Research Center | Methods and compositions for inhibiting the growth and/or proliferation of MYC-driven tumor cells |
EA201892766A1 (ru) | 2011-10-19 | 2019-08-30 | Фармасайкликс Элэлси | ПРИМЕНЕНИЕ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ БРУТОНА (Btk) |
TW201325593A (zh) | 2011-10-28 | 2013-07-01 | Celgene Avilomics Res Inc | 治療布魯頓(bruton’s)酪胺酸激酶疾病或病症之方法 |
BR112014013582A2 (pt) | 2011-12-09 | 2017-06-13 | Hoffmann La Roche | inibidores de quinase de tirosina de bruton |
IN2014MN01897A (es) | 2012-03-09 | 2015-07-10 | Carna Biosciences Inc | |
EP2838898B1 (en) | 2012-04-20 | 2017-01-18 | Advinus Therapeutics Limited | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
WO2013157021A1 (en) | 2012-04-20 | 2013-10-24 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
WO2013173518A1 (en) | 2012-05-16 | 2013-11-21 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
CA2881519A1 (en) | 2012-08-10 | 2014-02-13 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors |
KR102194611B1 (ko) | 2012-10-04 | 2020-12-23 | 유니버시티 오브 유타 리서치 파운데이션 | 티로신 수용체 키나아제 btk 억제제로서 치환된 n-(3-(피리미딘-4-일)페닐)아크릴아미드 유사체 |
US9512084B2 (en) * | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
-
2014
- 2014-11-13 US US14/540,140 patent/US9512084B2/en active Active
- 2014-11-27 JO JOP/2014/0341A patent/JO3314B1/ar active
- 2014-11-27 AR ARP140104439A patent/AR098549A1/es active IP Right Grant
- 2014-11-27 UY UY0001035858A patent/UY35858A/es active IP Right Grant
- 2014-11-28 JP JP2016535053A patent/JP6342495B2/ja active Active
- 2014-11-28 PT PT148212855T patent/PT3074386T/pt unknown
- 2014-11-28 CU CU2016000078A patent/CU24384B1/es unknown
- 2014-11-28 HR HRP20230585TT patent/HRP20230585T1/hr unknown
- 2014-11-28 TW TW103141506A patent/TWI652261B/zh active
- 2014-11-28 EA EA201691125A patent/EA031218B1/ru not_active IP Right Cessation
- 2014-11-28 LT LTEP14821285.5T patent/LT3074386T/lt unknown
- 2014-11-28 KR KR1020167013830A patent/KR102380539B1/ko active IP Right Grant
- 2014-11-28 LT LTEP17191467.4T patent/LT3299368T/lt unknown
- 2014-11-28 DK DK17191467.4T patent/DK3299368T3/da active
- 2014-11-28 WO PCT/IB2014/066422 patent/WO2015079417A1/en active Application Filing
- 2014-11-28 RS RS20200550A patent/RS60251B1/sr unknown
- 2014-11-28 MX MX2016006908A patent/MX367911B/es active IP Right Grant
- 2014-11-28 PE PE2016000683A patent/PE20160869A1/es unknown
- 2014-11-28 PT PT171914674T patent/PT3299368T/pt unknown
- 2014-11-28 PL PL14821285T patent/PL3074386T3/pl unknown
- 2014-11-28 NZ NZ718835A patent/NZ718835A/en unknown
- 2014-11-28 EP EP14821285.5A patent/EP3074386B1/en active Active
- 2014-11-28 MY MYPI2020002915A patent/MY191381A/en unknown
- 2014-11-28 HU HUE20158961A patent/HUE062248T2/hu unknown
- 2014-11-28 PT PT201589611T patent/PT3689865T/pt unknown
- 2014-11-28 TN TN2016000128A patent/TN2016000128A1/en unknown
- 2014-11-28 AP AP2016009158A patent/AP2016009158A0/en unknown
- 2014-11-28 RS RS20171206A patent/RS56657B1/sr unknown
- 2014-11-28 ES ES14821285.5T patent/ES2655527T3/es active Active
- 2014-11-28 RS RS20230437A patent/RS64275B1/sr unknown
- 2014-11-28 MA MA39055A patent/MA39055B1/fr unknown
- 2014-11-28 PL PL17191467T patent/PL3299368T3/pl unknown
- 2014-11-28 BR BR112016010397-1A patent/BR112016010397B1/pt active IP Right Grant
- 2014-11-28 UA UAA201603623A patent/UA117256C2/uk unknown
- 2014-11-28 EP EP20158961.1A patent/EP3689865B1/en active Active
- 2014-11-28 SI SI201432031T patent/SI3689865T1/sl unknown
- 2014-11-28 EP EP17191467.4A patent/EP3299368B1/en active Active
- 2014-11-28 NO NO14821285A patent/NO3074386T3/no unknown
- 2014-11-28 KR KR1020227009823A patent/KR102421388B1/ko active IP Right Grant
- 2014-11-28 SI SI201430536T patent/SI3074386T1/en unknown
- 2014-11-28 ES ES17191467T patent/ES2791525T3/es active Active
- 2014-11-28 HU HUE17191467A patent/HUE049794T2/hu unknown
- 2014-11-28 MY MYPI2016701223A patent/MY179059A/en unknown
- 2014-11-28 CN CN201910288376.XA patent/CN110172056B/zh active Active
- 2014-11-28 DK DK20158961.1T patent/DK3689865T3/da active
- 2014-11-28 CA CA2926908A patent/CA2926908C/en active Active
- 2014-11-28 CN CN201480058515.5A patent/CN105683181B/zh active Active
- 2014-11-28 AU AU2014356069A patent/AU2014356069B2/en active Active
- 2014-11-28 SI SI201431570T patent/SI3299368T1/sl unknown
- 2014-11-28 HU HUE14821285A patent/HUE037588T2/hu unknown
- 2014-11-28 EP EP23161775.4A patent/EP4219478A1/en active Pending
- 2014-11-28 FI FIEP20158961.1T patent/FI3689865T3/fi active
- 2014-11-28 DK DK14821285.5T patent/DK3074386T3/en active
- 2014-11-28 ES ES20158961T patent/ES2947770T3/es active Active
- 2014-11-28 PL PL20158961.1T patent/PL3689865T3/pl unknown
- 2014-11-28 LT LTEP20158961.1T patent/LT3689865T/lt unknown
-
2016
- 2016-04-05 ZA ZA2016/02275A patent/ZA201602275B/en unknown
- 2016-04-06 IL IL244943A patent/IL244943B/en active IP Right Grant
- 2016-04-21 US US15/135,296 patent/US20160235746A1/en not_active Abandoned
- 2016-04-28 PH PH12016500791A patent/PH12016500791A1/en unknown
- 2016-05-03 CL CL2016001055A patent/CL2016001055A1/es unknown
- 2016-05-27 CR CR20160244A patent/CR20160244A/es unknown
- 2016-05-27 SV SV2016005206A patent/SV2016005206A/es unknown
- 2016-06-20 EC ECIEPI201654826A patent/ECSP16054826A/es unknown
- 2016-10-06 HK HK16111636.9A patent/HK1223368A1/zh unknown
-
2017
- 2017-12-22 CY CY20171101345T patent/CY1119705T1/el unknown
- 2017-12-27 HR HRP20171999TT patent/HRP20171999T1/hr unknown
-
2018
- 2018-05-08 US US15/974,190 patent/US10457647B2/en active Active
- 2018-05-16 JP JP2018094772A patent/JP6667573B2/ja active Active
- 2018-09-10 HK HK18111597.4A patent/HK1252317A1/zh unknown
-
2019
- 2019-09-16 US US16/571,405 patent/US11180460B2/en active Active
-
2020
- 2020-05-12 HR HRP20200775TT patent/HRP20200775T1/hr unknown
- 2020-05-25 CY CY20201100478T patent/CY1122924T1/el unknown
-
2021
- 2021-10-22 US US17/508,054 patent/US11673868B2/en active Active
-
2023
- 2023-05-01 US US18/309,948 patent/US20230312483A1/en active Pending
- 2023-06-27 CY CY20231100301T patent/CY1126056T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2016001055A1 (es) | Compuestos derivados de fenil-aminopirimidina, inhibidores de la tirosina quinasa de bruton (btk), composicion farmaceutica; combinacion farmaceutica; útiles en el tratamiento de enfermedades autoinmunes, inflamatorias, alergicas, de las vias aereas, entre otras. | |
CL2013002063A1 (es) | Compuestos derivados de pirrolo(piridina, pirimidina o pirazina), inhibidores de serina/trionina cinasa; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer, infecciones inflamaciones y enfermedades autoinmune. | |
EA201591524A1 (ru) | Производные 2-аминопиримидина для лечения вирусных инфекций | |
CL2014002732A1 (es) | Compuestos derivados de imidazolil-pirimidinas sustituidas con amino-indolilo, inhibidores de la proteina quinasa syk; compuestos intermediarios; formulaciones farmaceuticas que los contienen; uso en el tratamiento de enfermedades tales como asma, epoc, rinitis alergica, entre otras. | |
EA202090291A3 (ru) | Производные бипиразола в качестве ингибиторов jak | |
CL2015002030A1 (es) | Dihidropirimidinomas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrofílica | |
CL2014002412A1 (es) | Compuestos derivados de pirido[4,3-d]pirimidina, como inhibidores de mek; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades inflamatorias, infecciones, trastornos autoinmunes, enfermedades metabolicas y enfermedades malignas, entre otras. | |
NI201500067A (es) | Compuestos de pirrolopirimidina como inhibidores de quinasa | |
EA201590215A1 (ru) | Макроциклические пурины для лечения вирусных инфекций | |
ECSP14013148A (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
EA201591887A1 (ru) | Макроциклические деазаоксипурины для лечения вирусных инфекций | |
MX365294B (es) | Inhibidores de proteína cinasa dependiente de adn. | |
CL2016001543A1 (es) | Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas. | |
BR112015009942A2 (pt) | derivados de tiofeno fundidos tricíclicos como inibidores de jak | |
CL2014002358A1 (es) | Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluoro-3-fenilquinazolin-4(3h)-ona; metodos de preparacion; composiciones farmaceuticas que las comprenden y uso en el tratamiento del cancer. | |
UY34545A (es) | Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios. | |
CL2013003472A1 (es) | Compuestos derivados de halogenoalquil-1,3-oxazinas sustituidas, inhibidores de la bace1 y/o bace2; procedimiento de obtencion; composicion farmaceutica que los comprende; su uso en el tratamiento y/o profilaxis de enfermedades tales como diabetes, alzheimer, als, enfermedades autoinmunes inflamatorias, cancer, entre otras. | |
CL2015003444A1 (es) | Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo | |
EA201590931A1 (ru) | Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций | |
MX2015011898A (es) | Compuestos de pirazolo y usos de los mismos. | |
CR20130617A (es) | Derivados de piridin-2(1h)-ona útiles como medicamentos para el tratamiento de trastornos mieloproliferativos, rechazo de trasplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias | |
EA201391719A1 (ru) | Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
EA201992133A1 (ru) | Производные пиперидино-пиримидина для лечения вирусных инфекций | |
CL2016003214A1 (es) | Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas | |
UY35625A (es) | Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos como inhibidores de quinasa |